Celcuity (CELC) closed at $65.57 on October 22, 2026, up 6.5% from the previous close, on volume of 1,351,824 shares (30-day average 1,527,480).
Data as of October 22, 2026.
22-Oct-2026
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and AnaptysBio (ANAB)
TipRanks (Thu, 22-Oct 9:40 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Celcuity Appoints David Gryska To Its Board Of Directors
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Market Chameleon (Wed, 30-Sep 5:19 AM ET)
Celcuity Announces That REVTORPYK (gedatolisib) Is Now Commercially Available In The United States
Globe Newswire (Wed, 30-Sep 8:00 AM ET)
Celcuity To Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
Globe Newswire (Wed, 26-Aug 8:30 AM ET)
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Aug 4:06 PM ET)
PRNewswire (Thu, 6-Aug 11:02 PM ET)
Globe Newswire (Tue, 4-Aug 5:43 PM ET)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of October 22, 2026, CELC stock price climbed to $65.57 with 1,351,824 million shares trading.
CELC has a beta of 2.54, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.18 to the broad based SPY ETF.
CELC has a market cap of $3.21 billion. This is considered a Mid Cap stock.
Last quarter Celcuity reported $0 in Revenue and -$1.07 earnings per share. This fell short of revenue expectation by $-400,000 and exceeded earnings estimates by $.01.
In the last 3 years, CELC traded as high as $151.02 and as low as $7.58.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CELC has underperformed the market in the last year with a return of +0.1%, while the SPY ETF gained +14.9%. In the last 3 month period, CELC fell short of the market, returning -28.5%, while SPY returned +2.3%. However, in the most recent 2 weeks CELC has outperformed the stock market by returning -0.3%, while SPY returned -1.7%.
CELC support price is $58.86 and resistance is $64.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.